Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 141

1.

In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist.

Takusagawa S, Miyashita A, Iwatsubo T, Usui T.

Xenobiotica. 2012 Dec;42(12):1187-96. doi: 10.3109/00498254.2012.700140. Epub 2012 Jul 27.

PMID:
22834478
[PubMed - indexed for MEDLINE]
2.

Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist.

Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T.

Xenobiotica. 2012 Oct;42(10):957-67. doi: 10.3109/00498254.2012.675095. Epub 2012 Apr 18.

PMID:
22509825
[PubMed - indexed for MEDLINE]
3.

Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.

Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, Gilbert D, LeCluyse EL, Sinz MW.

Drug Metab Dispos. 2003 Apr;31(4):439-46.

PMID:
12642470
[PubMed - indexed for MEDLINE]
Free Article
4.

In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran.

Paris BL, Ogilvie BW, Scheinkoenig JA, Ndikum-Moffor F, Gibson R, Parkinson A.

Drug Metab Dispos. 2009 Oct;37(10):2045-54. doi: 10.1124/dmd.109.028274. Epub 2009 Jul 16.

PMID:
19608694
[PubMed - indexed for MEDLINE]
Free Article
5.

Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.

Xing J, Kirby BJ, Whittington D, Wan Y, Goodlett DR.

Drug Metab Dispos. 2012 Sep;40(9):1757-64. doi: 10.1124/dmd.112.045765. Epub 2012 Jun 7.

PMID:
22679214
[PubMed - indexed for MEDLINE]
Free Article
6.

In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine.

Chen Y, Liu L, Laille E, Kumar G, Surapaneni S.

Cancer Chemother Pharmacol. 2010 Apr;65(5):995-1000. doi: 10.1007/s00280-010-1245-9. Epub 2010 Jan 30.

PMID:
20119716
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

In vitro assessment of cytochrome P450 inhibition and induction potential of felotaxel (SHR110008).

Ding Y, Jia Y, Lu C, Liu W, Yang J, Song Y, Zhu Y, Yang L, Ding L, Wen A.

Biomed Pharmacother. 2012 Jun;66(4):318-21. doi: 10.1016/j.biopha.2012.01.001. Epub 2012 Feb 17.

PMID:
22397757
[PubMed - indexed for MEDLINE]
8.

Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.

Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T, Kerbusch V, Kowalski D, Roy M, Marion A, Takusagawa S, van Gelderen M, Keirns J.

Clin Drug Investig. 2013 Jun;33(6):429-40. doi: 10.1007/s40261-013-0084-y.

PMID:
23625188
[PubMed - indexed for MEDLINE]
9.

In vitro study of the inhibition and induction of human cytochromes P450 by crystalline glucosamine sulfate.

Persiani S, Canciani L, Larger P, Rotini R, Trisolino G, Antonioli D, Rovati LC.

Drug Metabol Drug Interact. 2009;24(2-4):195-209.

PMID:
20408500
[PubMed - indexed for MEDLINE]
10.

An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes.

Nassar AE, King I, Paris BL, Haupt L, Ndikum-Moffor F, Campbell R, Usuki E, Skibbe J, Brobst D, Ogilvie BW, Parkinson A.

Drug Metab Dispos. 2009 Sep;37(9):1922-30. doi: 10.1124/dmd.109.027516. Epub 2009 Jun 11.

PMID:
19520774
[PubMed - indexed for MEDLINE]
Free Article
11.

The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.

Krauwinkel W, Dickinson J, Schaddelee M, Meijer J, Tretter R, van de Wetering J, Strabach G, van Gelderen M.

Eur J Drug Metab Pharmacokinet. 2014 Mar;39(1):43-52. doi: 10.1007/s13318-013-0133-1. Epub 2013 Jun 1.

PMID:
23728524
[PubMed - indexed for MEDLINE]
12.

In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil.

Robertson P, DeCory HH, Madan A, Parkinson A.

Drug Metab Dispos. 2000 Jun;28(6):664-71.

PMID:
10820139
[PubMed - indexed for MEDLINE]
Free Article
13.
14.

Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements.

Foti RS, Dickmann LJ, Davis JA, Greene RJ, Hill JJ, Howard ML, Pearson JT, Rock DA, Tay JC, Wahlstrom JL, Slatter JG.

Xenobiotica. 2008 Mar;38(3):264-80. doi: 10.1080/00498250701802514 .

PMID:
18274956
[PubMed - indexed for MEDLINE]
15.

Assessment of induction of cytochrome P450 by NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, in primary cultures of human hepatocytes and in female rat liver.

Morioka Y, Nishimura M, Imai T, Suzuki S, Harada M, Satoh T, Naito S.

Drug Metab Pharmacokinet. 2006 Feb;21(1):19-28.

PMID:
16547390
[PubMed - indexed for MEDLINE]
Free Article
16.

The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.

Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM.

Toxicol Appl Pharmacol. 2004 Sep 15;199(3):193-209. Review.

PMID:
15364537
[PubMed - indexed for MEDLINE]
17.

Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes.

Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH.

Biopharm Drug Dispos. 2000 Dec;21(9):353-64.

PMID:
11523064
[PubMed - indexed for MEDLINE]
18.

In vitro studies investigating the interactions between degarelix, a decapeptide gonadotropin-releasing hormone blocker, and cytochrome P450.

Sonesson A, Rasmussen BB.

Basic Clin Pharmacol Toxicol. 2011 Sep;109(3):195-202. doi: 10.1111/j.1742-7843.2011.00709.x. Epub 2011 May 23.

PMID:
21496210
[PubMed - indexed for MEDLINE]
19.

Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.

Renwick AB, Surry D, Price RJ, Lake BG, Evans DC.

Xenobiotica. 2000 Oct;30(10):955-69.

PMID:
11315104
[PubMed - indexed for MEDLINE]
20.

In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.

Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, Maxwell BD, Chen SY, He K, Goosen TC, Humphreys WG, Grossman SJ.

Drug Metab Dispos. 2010 Mar;38(3):448-58. doi: 10.1124/dmd.109.029694. Epub 2009 Nov 25. Erratum in: Drug Metab Dispos. 2010 May;38(5):887. Frost, Charles A [corrected to Frost, Charles E].

PMID:
19940026
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk